Immunohistochemistry or IHC
Comprehensive epithelial biomarker analysis of malignant mesothelioma: EpCAM positivity is a potential diagnostic pitfall
Cancer Cytopathology 2023 April 17 [Link] Yili Zhu, Simone Moore, Aihui Wang, Elizabeth George, Grace M Allard, Diane M Libert, Alarice C Lowe Abstract Background: Epithelial cell adhesion molecule (EpCAM) is frequently used to distinguish carcinoma from background mesothelial cells during cytologic examination of body cavity fluids. Previously, the authors identified one malignant mesothelioma case…
Read MoreOne Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
International Journal of Molecular Sciences 2023 March 28 [Link] Thomas Hager, Sabrina Borchert, Michael Wessolly, Alexander Mathilakathu, Elena Mairinger, Jens Kollmeier, Thomas Mairinger, Balazs Hegedus, Kristina Greimelmaier, Jeremias Wohlschlaeger, Ken Herrmann, Fabian Dominik Mairinger Abstract Malignant pleural mesothelioma (MPM) is a mainly asbestos-related tumour associated with a very poor prognosis. Therapeutic approaches include multimodal therapy…
Read MoreHigh mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma
Histopathology 2023 April 11 [Link] Gerard J Chu, Anthony Linton, Steven Kao, Sonja Klebe, Stephen Adelstein, Dannel Yeo, John E J Rasko , Wendy A Cooper Abstract Aims: Mesothelin (MSLN) is a cancer-associated antigen that is overexpressed in malignancies such as mesothelioma, pancreatic and ovarian cancer. It is also a target for novel personalised therapies,…
Read MoreTROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy
Lung Cancer 2023 April [Link] Luca Hegedüs, Özlem Okumus, Fabian Mairinger, Till Ploenes, Sebastian Reuter, Martin Schuler, Anja Welt, Silvia Vega-Rubin-de-Celis, Dirk Theegarten, Agnes Bankfalvi, Clemens Aigner, Balazs Hegedüs Abstract Objectives: Malignant pleural mesothelioma (MPM) is an aggressive cancer which at large is not amenable to curative surgery. Despite the recent approval of immune checkpoint…
Read MoreA novel prognostic nomogram for predicting survival in diffuse pleural mesothelioma
Pathology 2023 February 4 [Link] Yagiz Aksoy, Angela Chou, Mahiar Mahjoub, Amy Sheen, Loretta Sioson, Mahsa S Ahadi, Anthony J Gill, Talia L Fuchs Abstract Recent advances in the management of diffuse pleural mesothelioma (DPM) have increased interest in prognostication and risk stratification on the basis that maximum benefit of combination immunotherapy appears to be…
Read MoreNeurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma
Modern Pathology 2023 March [Link] Yan Li, Soo-Ryum Yang, Ying-Bei Chen, Prasad S Adusumilli, Ann Bialik, Francis M Bodd, Marc Ladanyi, Jessica Lopardo, Michael D Offin, Valerie W Rusch, William D Travis, Marjorie G Zauderer, Jason C Chang, Jennifer L Sauter Abstract Neurofibromatosis type 2 (NF2) loss occurs in approximately 30% to 50% of diffuse…
Read MoreMedical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma
Proceedings of the Japan Academy 2023 [Link] Shoutaro Tsuji, Kohzoh Imai Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleural cavity. Pathologically distinguishing MPM from other pleural lesions is often difficult. We searched for marker antigens to facilitate the pathological diagnosis of MPM and found useful markers for the pathological detection of…
Read MoreIdentification of Highly Sensitive Pleural Effusion Protein Biomarkers for Malignant Pleural Mesothelioma by Affinity-Based Quantitative Proteomics
Cancers 2023 January 19 [Link] Nicolai B Palstrøm, Martin Overgaard, Peter Licht, Hans C Beck Abstract Malignant pleural mesothelioma (MPM) is an asbestos-associated, highly aggressive cancer characterized by late-stage diagnosis and poor prognosis. Gold standards for diagnosis are pleural biopsy and cytology of pleural effusion (PE), both of which are limited by low sensitivity and…
Read MoreCD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma
The Journal of Pathology. Clinical Research 2023 February 8 [Link] Shingo Inaguma, Akane Ueki, Jerzy Lasota, Masayuki Komura, Asraful Nahar Sheema, Piotr Czapiewski, Renata Langfort, Janusz Rys, Joanna Szpor, Piotr Waloszczyk, Krzysztof Okoń, Wojciech Biernat, David S Schrump, Raffit Hassan, Markku Miettinen, Satoru Takahashi Abstract Diffuse pleural mesothelioma (PM) is a highly aggressive tumour typically…
Read MoreThe Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy
Asian Pacific Journal of Cancer Prevention 2023 January 1 [Link] Nagwa Ismail Wahba, Ola Khorshid, Fatma Abo Elkasem, Abeer Bahnassy, Rabab Gaafer Abstract Background: A rare yet severe neoplasia called malignant pleural mesothelioma (MPM) typically manifests itself in advanced stages. Despite some improvements in the treatment of patients with MPM, this malignancy continues to have…
Read More